摘要
本文首先介绍新型免疫靶点PD-1及其配体PD-L1和PD-L2结合的分子机制、信号通路以及介导免疫耐受的生理意义。在此基础上,本文又总结了国内外报道的新型药物和研究进展,用诸多临床实例和数据分析单药治疗和联合治疗在黑色素瘤、非小细胞肺癌等肿瘤治疗中的疗效。同时,提出了在药物安全性、PD-1/PD-L2的分子机制、单抗和药物抗病毒作用等方面研究的不足和前景。
This article concentrates on the new immune target,PD-1 and its ligands PD-L1 and PD-L2,including its molecular mechanism,signaling pathway and the physiologic significance of the immune tolerance.Based on basic mechanisms,some newly reported drugs and research findings are reviewed,the therapeutic effect of monotherapy and combined drug therapy are analyzed on melanoma and non-small cell lung carcinoma（NSCLC） using data collected from large numbers of clinical cases.Besides,it＇s pointed out that the limitations of the present study on drug safety,molecular mechanism of PD-1/PD-L2,monoclonal antibody and the antiviral effect still exist.Therefore,the research about PD-1 is worth trying.
出处
《生命的化学》
CAS
CSCD
2017年第3期341-348,共8页
Chemistry of Life
基金
国家自然科学基金项目(NSFC41306197)
